

You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
Antibody Characterization Report for Serine/threonine-protein kinase Nek1
Antibody Characterization Report for Serine/threonine-protein kinase Nek1
Head to head comparison of available commercial antibodies against Serine/threonine-protein kinase Nek1 by immunoblot (Western blot), immunoprecipitation and immunofluorescence. This work is part of the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.
NEK1, antibody characterization, Q96PY6, NimA-related protein kinase 1, antibody validation, Amyotrophic lateral sclerosis, Serine/threonine-protein kinase Nek1, Never in mitosis A-related kinase 1, ALS-RAP
NEK1, antibody characterization, Q96PY6, NimA-related protein kinase 1, antibody validation, Amyotrophic lateral sclerosis, Serine/threonine-protein kinase Nek1, Never in mitosis A-related kinase 1, ALS-RAP
18 Research products, page 1 of 2
- 2021IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2023IsAmongTopNSimilarDocuments
- 2023IsAmongTopNSimilarDocuments
- 2023IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average visibility views 190 download downloads 126 citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average Powered byBIP!
- 190views126downloads



Head to head comparison of available commercial antibodies against Serine/threonine-protein kinase Nek1 by immunoblot (Western blot), immunoprecipitation and immunofluorescence. This work is part of the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.